Final answer:
Glivec, or imatinib, is an essential medication for treating Chronic myelogenous leukemia by inhibiting the BCR-ABL tyrosine kinase, which slows down the growth of leukemic cells and induces their programmed cell death.
Step-by-step explanation:
Glivec, also known as imatinib, plays a critical role in the treatment of Chronic myelogenous leukemia (CML). CML is a type of cancer that originates in the blood-forming cells of the bone marrow and is characterized by the uncontrolled growth of myeloid cells. Glivec targets and inhibits the activity of the BCR-ABL tyrosine kinase, a protein that is produced by the Philadelphia chromosome abnormality in CML cells. This abnormal protein is responsible for the proliferation of cancer cells. By inhibiting the BCR-ABL kinase, Glivec impedes the growth and encourages apoptosis or programmed cell death of the leukemic cells.
The efficacy of Glivec has transformed CML from a fatal disease to a manageable chronic condition for many patients. It is a front-line therapy that has significantly improved survival rates and quality of life for individuals with CML.
Due to its targeted mechanism of action, Glivec has less severe side effects compared to traditional chemotherapy. However, patients may experience some adverse reactions such as edema, nausea, and muscle cramps. Regular monitoring and dose adjustments are essential for managing these side effects and ensuring effective treatment.